Insect-derived cecropins display activity against Acinetobacter baumannii in a whole-animal high-throughput Caenorhabditis elegans model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1728-1737

  Jayamani, Elamparithi ^a,b   Rajamuthiah, Rajmohan ^a,b   Larkins Ford, Jonah ^b   Fuchs, Beth Burgwyn ^a,b   Conery, Annie L ^b   Vilcinskas, Andreas ^c   Ausubel, Frederick M ^b   Mylonakisa, Eleftherios ^a,b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CECROPIN; CECROPIN A; DIMETHYL SULFOXIDE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ACINETOBACTER INFECTION; AEDES AEGYPTI; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DISK DIFFUSION; DRUG SYNTHESIS; ESCHERICHIA COLI; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; IMAGE ANALYSIS; LIQUID CULTURE; MEMBRANE PERMEABILITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR LIBRARY; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS; ACINETOBACTER BAUMANNII; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INSECT; METABOLISM; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ACINETOBACTER BAUMANNII; ANIMALS; ANTI-BACTERIAL AGENTS; CAENORHABDITIS ELEGANS; CECROPINS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; INSECTS;

EID: 84923253954     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04198-14     Document Type: Article

References (76)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
2. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 32(Suppl 2):S104-S113. http://dx.doi.org/10.1086/320183.
3. Maragakis LL, Perl TM. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 46:1254-1263. http://dx.doi.org/10.1086/529198.
4. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendía JL, Ortiz C, Cobacho AR. 1996. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis 22:1026-1032. http://dx.doi.org/10.1093/clinids/22.6.1026.
5. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S, Lindler L, Mancuso J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G, Petersen K, Endy T, Petruccelli B. 2007. An outbreak of multidrugresistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 44:1577-1584. http://dx.doi.org/10.1086/518170.
6. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417-433. http://dx.doi.org/10.1128/MMBR.00016-10.
7. Tan SY-Y, Chua SL, Liu Y, Høiby N, Andersen LP, Givskov M, Song Z, Yang L. 2013. Comparative genomic analysis of rapid evolution of an extreme-drug-resistant Acinetobacter baumannii clone. Genome Biol Evol 5:807-818. http://dx.doi.org/10.1093/gbe/evt047.
8. Hood MI, Mortensen BL, Moore JL, Zhang Y, Kehl-Fie TE, Sugitani N, Chazin WJ, Caprioli RM, Skaar EP. 2012. Identification of an Acinetobacter baumannii zinc acquisition system that facilitates resistance to calprotectin-mediated zinc sequestration. PLoS Pathog 8:e1003068. http://dx.doi.org/10.1371/journal.ppat.1003068.
9. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357.
10. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG, Antimicrobial Availability Task Force of the Infectious Diseases Society of America. 2006. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42:657-668. http://dx.doi.org/10.1086/499819.
11. Perron GG, Zasloff M, Bell G. 2006. Experimental evolution of resistance to an antimicrobial peptide. Proc Biol Sci 273:251-256. http://dx.doi.org/10.1098/rspb.2005.3301.
12. Fournier P-E, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, Richet H, Robert C, Mangenot S, Abergel C, Nordmann P, Weissenbach J, Raoult D, Claverie J-M. 2006. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2:e7. http://dx.doi.org/10.1371/journal.pgen.0020007.
13. Sahl JW, Gillece JD, Schupp JM, Waddell VG, Driebe EM, Engelthaler DM, Keim P. 2013. Evolution of a pathogen: a comparative genomics analysis identifies a genetic pathway to pathogenesis in Acinetobacter. PLoS One 8:e54287. http://dx.doi.org/10.1371/journal.pone.0054287.
14. Saugar JM, Rodríguez-Hernández MJ, de la Torre BG, Pachón-Ibañez ME, Fernández-Reyes M, Andreu D, Pachón J, Rivas L. 2006. Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother 50:1251-1256. http://dx.doi.org/10.1128/AAC.50.4.1251-1256.2006.
15. Ewbank JJ, Zugasti O. 2011. C. Elegans: model host and tool for antimicrobial drug discovery. Dis Model Mech 4:300-304. http://dx.doi.org/10.1242/dmm.006684.
16. Moy TI, Conery AL, Larkins-Ford J, Wu G, Mazitschek R, Casadei G, Lewis K, Carpenter AE, Ausubel FM. 2009. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 4:527-533. http://dx.doi.org/10.1021/cb900084v.
17. Tan MW, Mahajan-Miklos S, Ausubel FM. 1999. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci U S A 96:715-720. http://dx.doi.org/10.1073/pnas.96.2.715.
18. Garsin DA, Sifri CD, Mylonakis E, Qin X, Singh KV, Murray BE, Calderwood SB, Ausubel FM. 2001. A simple model host for identifying Gram-positive virulence factors. Proc Natl Acad Sci U S A 98:10892-10897. http://dx.doi.org/10.1073/pnas.191378698.
19. Desalermos A, Tan X, Rajamuthiah R, Arvanitis M, Wang Y, Li D, Kourkoumpetis TK, Fuchs BB, Mylonakis E. 2015. A multi-host approach for the systematic analysis of virulence factors in Cryptococcus neoformans. J Infect Dis 211:298-305. http://dx.doi.org/10.1093/infdis/jiu441.
20. Rajamuthiah R, Mylonakis E. 2014. Effector triggered immunity: activation of innate immunity in metazoans by bacterial effectors. Virulence 5:697-702. http://dx.doi.org/10.4161/viru.29091.
21. Marsh EK, May RC. 2012. Caenorhabditis elegans, a model organism for investigating immunity. Appl Environ Microbiol 78:2075-2081. http://dx.doi.org/10.1128/AEM.07486-11.
22. Kaletta T, Hengartner MO. 2006. Finding function in novel targets: C. Elegans as a model organism. Nat Rev Drug Discov 5:387-398. http://dx.doi.org/10.1038/nrd2031.
23. Mylonakis E, Casadevall A, Ausubel FM. 2007. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog 3:e101. http://dx.doi.org/10.1371/journal.ppat.0030101.
24. Dolla NK, Chen C, Larkins-Ford J, Rajamuthiah R, Jagadeesan S, Conery AL, Ausubel FM, Mylonakis E, Bremner JB, Lewis K, Kelso MJ. 2014. On the mechanism of berberine-INF55 (5-nitro-2-phenylindole) hybrid antibacterials. Aust J Chem 67:1471. http://dx.doi.org/10.1071/CH14426.
25. Wiesner J, Vilcinskas A. 2010. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 1:440-464. http://dx.doi.org/10.4161/viru.1.5.12983.
26. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. http://dx.doi.org/10.1038/415389a.
27. Fjell CD, Hiss JA, Hancock REW, Schneider G. 2012. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11:37-51. http://dx.doi.org/10.1038/nrd3591.
28. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238-250. http://dx.doi.org/10.1038/nrmicro1098.
29. Yeaman MR. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55:27-55. http://dx.doi.org/10.1124/pr.55.1.2.
30. Vilcinskas A, Mukherjee K, Vogel H. 2012. Expansion of the antimicrobial peptide repertoire in the invasive ladybird Harmonia axyridis. Proc R Soc B Biol Sci 280:20122113. http://dx.doi.org/10.1098/rspb.2012.2113.
31. Hilchie AL, Wuerth K, Hancock REW. 2013. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9:761-768. http://dx.doi.org/10.1038/nchembio.1393.
32. Bowdish DME, Davidson DJ, Scott MG, Hancock REW. 2005. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 49:1727-1732. http://dx.doi.org/10.1128/AAC.49.5.1727-1732.2005.
33. Beanan MJ, Strome S. 1992. Characterization of a germ-line proliferation mutation in C. Elegans. Development 116:755-766.
34. Miyata S, Begun J, Troemel ER, Ausubel FM. 2008. DAF-16-dependent suppression of immunity during reproduction in Caenorhabditis elegans. Genetics 178:903-918. http://dx.doi.org/10.1534/genetics.107.083923.
35. Kim DH, Feinbaum R, Alloing G, Emerson FE, Garsin DA, Inoue H, Tanaka-Hino M, Hisamoto N, Matsumoto K, Tan M-W, Ausubel FM. 2002. A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297:623-626. http://dx.doi.org/10.1126/science.1073759.
36. Anastassopoulou CG, Fuchs BB, Mylonakis E. 2011. Caenorhabditis elegans-based model systems for antifungal drug discovery. Curr Pharm Des 17:1225-1233. http://dx.doi.org/10.2174/138161211795703753.
37. Kirienko NV, Kirienko DR, Larkins-Ford J, Wählby C, Ruvkun G, Ausubel FM. 2013. Pseudomonas aeruginosa disrupts Caenorhabditis elegans iron homeostasis, causing a hypoxic response and death. Cell Host Microbe 13:406-416. http://dx.doi.org/10.1016/j.chom.2013.03.003.
38. Kamentsky L, Jones TR, Fraser A, Bray M-A, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE. 2011. Improved structure, function and compatibility for CellProfiler: modular highthroughput image analysis software. Bioinformatics 27:1179-1180. http://dx.doi.org/10.1093/bioinformatics/btr095.
39. Zhang J, Chung T, Oldenburg K. 1999. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73. http://dx.doi.org/10.1177/108705719900400206.
40. Altincicek B, Knorr E, Vilcinskas A. 2008. Beetle immunity: identification of immune-inducible genes from the model insect Tribolium castaneum. Dev Comp Immunol 32:585-595. http://dx.doi.org/10.1016/j.dci.2007.09.005.
41. Altincicek B, Vilcinskas A. 2009. Septic injury-inducible genes in medicinal maggots of the green blow fly Lucilia sericata. Insect Mol Biol 18:119-125. http://dx.doi.org/10.1111/j.1365-2583.2008.00856.x.
42. Vilcinskas A. 2011. Anti-infective therapeutics from the Lepidopteran model host Galleria mellonella. Curr Pharm Des 17:1240-1245. http://dx.doi.org/10.2174/138161211795703799.
43. Vogel H, Altincicek B, Glöckner G, Vilcinskas A. 2011. A comprehensive transcriptome and immune-gene repertoire of the lepidopteran model host Galleria mellonella. BMC Genomics 12:308. http://dx.doi.org/10.1186/1471-2164-12-308.
44. Mukherjee K, Abu Mraheil M, Silva S, Müller D, Cemic F, Hemberger J, Hain T, Vilcinskas A, Chakraborty T. 2011. Anti-Listeria activities of Galleria mellonella hemolymph proteins. Appl Environ Microbiol 77: 4237-4240. http://dx.doi.org/10.1128/AEM.02435-10.
45. Sowa-Jasiłek A, Zdybicka-Barabas A, Staçzek S, Wydrych J, Mak P, Jakubowicz T, Cytryńska M. 2014. Studies on the role of insect hemolymph polypeptides: Galleria mellonella anionic peptide 2 and lysozyme. Peptides 53:194-201. http://dx.doi.org/10.1016/j.peptides.2014.01.012.
46. Rajamuthiah R, Fuchs BB, Jayamani E, Kim Y, Larkins-Ford J, Conery A, Ausubel FM, Mylonakis E. 2014. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS One 9:e89189. http://dx.doi.org/10.1371/journal.pone.0089189.
47. Jorgensen JH, Ferraro MJ. 2009. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis 49:1749-1755. http://dx.doi.org/10.1086/647952.
48. Moule MG, Monack DM, Schneider DS. 2010. Reciprocal analysis of Francisella novicida infections of a Drosophila melanogaster model reveal host-pathogen conflicts mediated by reactive oxygen and imd-regulated innate immune response. PLoS Pathog 6:e1001065. http://dx.doi.org/10.1371/journal.ppat.1001065.
49. Silvestro L, Weiser JN, Axelsen PH. 2000. Antibacterial and antimembrane activities of cecropin A in Escherichia coli. Antimicrob Agents Chemother 44:602-607. http://dx.doi.org/10.1128/AAC.44.3.602-607.2000.
50. Saugar JM, Alarcón T, López-Hernández S, López-Brea M, Andreu D, Rivas L. 2002. Activities of polymyxin B and cecropin A-melittin peptide CA(1-8)M(1-18) against a multiresistant strain of Acinetobacter baumannii. Antimicrob Agents Chemother 46:875-878. http://dx.doi.org/10.1128/AAC.46.3.875-878.2002.
51. Nonejuie P, Burkart M, Pogliano K, Pogliano J. 2013. Bacterial cytological profiling rapidly identifies the cellular pathways targeted by antibacterial molecules. Proc Natl Acad SciUS A 110:16169-16174. http://dx.doi.org/10.1073/pnas.1311066110.
52. Cavallarin L, Andreu D, San Segundo B. 1998. Cecropin A-derived peptides are potent inhibitors of fungal plant pathogens. Mol Plant Microbe Interact 11:218-227. http://dx.doi.org/10.1094/MPMI.1998.11.3.218.
53. Dorsey CW, Beglin MS, Actis LA. 2003. Detection and analysis of iron uptake components expressed by Acinetobacter baumannii clinical isolates. J Clin Microbiol 41:4188-4193. http://dx.doi.org/10.1128/JCM.41.9.4188-4193.2003.
54. Eijkelkamp BA, Hassan KA, Paulsen IT, Brown MH. 2011. Investigation of the human pathogen Acinetobacter baumannii under iron limiting conditions. BMC Genomics 12:126. http://dx.doi.org/10.1186/1471-2164-12-126.
55. Nwugo CC, Gaddy JA, Zimbler DL, Actis LA. 2011. Deciphering the iron response in Acinetobacter baumannii: a proteomics approach. J Proteomics 74:44-58. http://dx.doi.org/10.1016/j.jprot.2010.07.010.
56. Dorsey CW, Tomaras AP, Connerly PL, Tolmasky ME, Crosa JH, Actis LA. 2004. The siderophore-mediated iron acquisition systems of Acinetobacter baumanniiATCC19606 and Vibrio anguillarum 775 are structurally and functionally related. Microbiology 150:3657-3667. http://dx.doi.org/10.1099/mic.0.27371-0.
57. Ruzin A, Keeney D, Bradford PA. 2007. AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 59:1001-1004. http://dx.doi.org/10.1093/jac/dkm058.
58. Rangarajan N, Bakshi S, Weisshaar JC. 2013. Localized permeabilization of E. coli membranes by the antimicrobial peptide cecropin A. Biochemistry 52:6584-6594. http://dx.doi.org/10.1021/bi400785j.
59. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
60. Rice LB. 2008. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197:1079-1081. http://dx.doi.org/10.1086/533452.
61. Chopra S, Torres-Ortiz M, Hokama L, Madrid P, Tanga M, Mortelmans K, Kodukula K, Galande AK. 2010. Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii. J Antimicrob Chemother 65:2598-2601. http://dx.doi.org/10.1093/jac/dkq353.
62. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ. 1994. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344:1329-1332. http://dx.doi.org/10.1016/S0140-6736(94)90694-7.
63. Karageorgopoulos DE, Falagas ME. 2008. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 8:751-762. http://dx.doi.org/10.1016/S1473-3099(08)70279-2.
64. Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC, Mylonakis E. 2008. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A 105:14585-14590. http://dx.doi.org/10.1073/pnas.0805048105.
65. Smith MG, Des Etages SG, Snyder M. 2004. Microbial synergy via an ethanol-triggered pathway. Mol Cell Biol 24:3874-3884. http://dx.doi.org/10.1128/MCB.24.9.3874-3884.2004.
66. Smith MG, Gianoulis TA, Pukatzki S, Mekalanos JJ, Ornston LN, Gerstein M, Snyder M. 2007. New insights into Acinetobacter baumannii pathogenesis revealed by high-density pyrosequencing and transposon mutagenesis. Genes Dev 21:601-614. http://dx.doi.org/10.1101/gad.1510307.
67. Kawamura-Sato K, Wachino J-I, Kondo T, Ito H, Arakawa Y. 2008. Reduction of disinfectant bactericidal activities in clinically isolated Acinetobacter species in the presence of organic material. J Antimicrob Chemother 61:568-576. http://dx.doi.org/10.1093/jac/dkm498.
68. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, Łukasiak J, Scalise G. 2003. Comparative activities of cecropin A, melittin, and cecropin A-melittin peptide CA(1-7)M(2-9)NH2 against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. Peptides 24:1315-1318. http://dx.doi.org/10.1016/j.peptides.2003.08.003.
69. Fox MA, Thwaite JE, Ulaeto DO, Atkins TP, Atkins HS. 2012. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II. Peptides 33:197-205. http://dx.doi.org/10.1016/j.peptides.2012.01.013.
70. Hetru C, Troxler L, Hoffmann JA. 2003. Drosophila melanogaster antimicrobial defense. J Infect Dis 187(Suppl 2):S327-S334. http://dx.doi.org/10.1086/374758.
71. Wang Y-P, Lai R. 2010. Insect antimicrobial peptides: structures, properties and gene regulation. Zool Res 31:27-34. http://dx.doi.org/10.3724/SP.J.1141.2010.01027.
72. Cai Y, Cao X, Aballay A. 2014. Whole-animal chemical screen identifies colistin as a new immunomodulator that targets conserved pathways. mBio 5:e01235-14. http://dx.doi.org/10.1128/mBio.01235-14.
73. Pukkila-Worley R, Feinbaum R, Kirienko NV, Larkins-Ford J, Conery AL, Ausubel FM. 2012. Stimulation of host immune defenses by a small molecule protects C. Elegans from bacterial infection. PLoS Genet 8:e1002733. http://dx.doi.org/10.1371/journal.pgen.1002733.
74. Mansour SC, Pena OM, Hancock REW. 2014. Host defense peptides: front-line immunomodulators. Trends Immunol 35:443-450. http://dx.doi.org/10.1016/j.it.2014.07.004.
75. Suttmann H, Retz M, Paulsen F, Harder J, Zwergel U, Kamradt J, Wullich B, Unteregger G, Stöckle M, Lehmann J. 2008. Antimicrobial peptides of the cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol 8:5. http://dx.doi.org/10.1186/1471-2490-8-5.
76. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53: 2605-2609. http://dx.doi.org/10.1128/AAC.01533-08.